Navigation Links
Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells
Date:1/20/2011

GAITHERSBURG, Md., Jan. 20, 2011 /PRNewswire/ -- MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors. The study, published in the February 1 issue of Cancer Research (a journal of the American Association for Cancer Research), suggests that MEDI-573 inhibits multiple biological pathways related to cancer.  

MEDI-573 is the only human monoclonal antibody (MAb) currently under clinical development that neutralizes both insulin-like growth factor (IGF)-I and IGF-II, growth hormones that regulate cell growth, survival, differentiation, and transformation (i.e., the process of acquiring cancerous characteristics). This MedImmune compound specifically inhibits IGF signaling through two important pathways: IGF-1R and IR-A (insulin receptor isoform A). Unlike the other IGF-1R-targeting MAbs in development that target only IGF-1R, MEDI-573 neutralizes both the receptors IGF-1R and IR-A as well as their hybrid receptors.  In addition, MEDI-573 spares the insulin receptor isoform B (IR-B), which interacts with insulin and is crucial for the metabolism of glucose – the body's main source of energy. Therapies that affect IR-B have been shown to raise or drop blood sugar levels, both of which can cause serious health problems. Preliminary data from MedImmune's first-time-in-human study suggest that MEDI-573 does not alter glucose homeostasis.

"MEDI-573 represents an innovative approach for the treatment of solid tumors with the potential for greater and more consistent inhibition of cancer cell growth than treatments that only target one pathway," said Jin Gao, Ph.D., Scientist II in Oncology Research at MedImmune and lead author of the study.  "The data from our pre-clinical studies are highly promising.  Ongoing studies in humans will pr
'/>"/>

SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
3. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
4. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
5. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
6. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
7. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
8. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
9. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
10. Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps
11. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 2013 was ... Scottsdale’s Brain State Technologies®. They saw continued independent research ... Center who were awarded a $1 million grant from ... in “Brain and Behavior” a peer reviewed journal, Amy ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... at the University of Central Florida have developed a ... more sensitive tool to detect pathogens associated with inflammatory ... nanoparticle-based technique also may be used for detection of ... they hide deep in human tissue and are able ...
... 2012 Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company ... offer shares of its common stock and warrants to purchase ... The offering is subject to market and other conditions, and ... the offering may be completed, or as to the actual ...
... wholly owned subsidiary of British company Innovative Carbon Limited today ... 10th April to 13th. , Graphene, a sheet of carbon ... wonder material. First isolated at Manchester University in 2004, ... race has been on to produce it commercially. To ...
Cached Biology Technology:UCF scientists use nanotechnology to hunt for hidden pathogens 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 2Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants 3UK company to demonstrate their commercially effective graphene production process 2
(Date:7/8/2014)... OhioThe future health of the world,s coral reefs and ... on the ability of one tiny symbiotic sea creature ... of algae it cooperates with. , In the first ... University discovered that coralstiny reef-forming animals that live symbiotically ... of heat stress, called "bleaching," when they keep large ...
(Date:7/8/2014)... Think of your next exercise workout as a "fun run" or ... of it as exercise or as a workout and you,ll later ... findings from the Cornell Food and Brand Lab study involved two ... a small lake and were either told it was going to ... the first study, 56 adults completed their walk and were then ...
(Date:7/8/2014)... NY, July 8, 2014Novel oligonucleotide-based drugs in development ... diseases. A group of industry and regulatory scientists ... recommendations for evaluating the pharmacological safety of oligonucleotide ... Acid Therapeutics , a peer-reviewed journal from Mary ... on the Nucleic Acid Therapeutics ...
Breaking Biology News(10 mins):For corals adapting to climate change, it's survival of the fattest -- and most flexible 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 3For corals adapting to climate change, it's survival of the fattest -- and most flexible 4
... issue of G&D report on the discovery of ... The studies from Drs. Alexander Stark and Manolis ... Lai (MSKCC) and colleagues, both reveal that antisense ... the novel miRNA precursor mir-iab-8, which is processed ...
... doctors treating life-threatening emergencies such as allergy attacks may give ... Adrenaline is stored in salt water in glass ampoules ... The amount of adrenaline contained in the ampoule is usually ... per 1 mL of salt water) and a ratio (1 ...
... team at Weill Cornell Medical College in New York City ... production of an immune system cytokine called interleukin-10 (IL-10). ... in a biochemical pathway that,s long been tied to disorders ... AIDS. "IL-10 production has to be kept in a ...
Cached Biology News:Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling 22 genes are important key to regulating immune response 22 genes are important key to regulating immune response 3